Enhanced TGF-βR chimeric receptor and its application
By expressing enhanced TGF-βR chimeric receptors on the immune cell membrane, binding to tumor antigens and using IL-6 signaling, the problem of TGF-β inhibiting immune function is solved, and the killing of CAR-T cells on solid tumors is significantly improved. abilities have promoted the application of CAR-T therapy in solid tumors.
Patent Information
- Application Number
- CN202310170006.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-27
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-02-27
AI Technical Summary
TGF-β is widely expressed in solid tumors, inhibiting the function of immune cells, resulting in poor effectiveness of CAR-T therapy in solid cancer treatment, and tumor cells are resistant to inhibitors and are difficult to effectively kill.
Design an enhanced TGF-βR chimeric receptor that binds the TGF-βR2 extracellular domain and the IL-6 receptor intracellular domain, is connected through the transmembrane domain, is expressed on the immune cell membrane, binds to tumor antigens and utilizes IL-6 activates the signaling domain, reduces the immunosuppression of TGF-β, and enhances the killing ability of CAR-T cells.
In the environment of high concentration of TGF-β, the killing effect of T cells on solid tumors is significantly improved, the efficacy of CAR-T therapy is enhanced, the resistance of tumor cells to inhibitors is overcome, and the killing rate of gastric cancer cells is improved.
Smart Images

Figure CN116284449B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological preparation technology, and in particular to an enhanced TGF-βR chimeric receptor and application thereof. Background Art
[0002] Chimeric antigen receptor (CAR)-modified immune cells, such as T cells (CAR-T), are currently the most promising immunotherapy methods, especially for refractory leukemia and lymphoma, and have achieved great results. However, the effect in the treatment of solid cancers is not satisfactory. Among the many cytokines that inhibit immune cells, transforming growth factor β (TGF-β) has the most obvious inhibitory effect on T cells. TGF-β is expressed at high levels in most solid tumors such as ovarian cancer, lung cancer, and colorectal cancer. It not only directly affects the function of effector T cells, but also inhibits their proliferation and induces differentiation into suppressor T cells. TGF-β can also inhibit the cytotoxicity of natural killer cells, monocytes, and neutrophils.
[0003] In the malignant tumor microenvironment, there are multiple mechanisms that can inhibit the response of immune cells, such as soluble factors that inhibit cell-cell binding. Inhibition of these factors, such as PD-1 and CTLA-4, can eliminate some tumor cells to a certain extent, but if resistant tumors develop in the later stage, they will not respond to the effects of these inhibitors.
[0004] However, TGFβ is found to be expressed in large quantities in many tumor cells, especially gastric cancer cells. TGFβ accumulates in large quantities in tumor tissues and induces the expression of many extracellular mediators of change. TGFβ plays an important role in regulating the initiation, development, maintenance and regression of immune responses and is an effective immunosuppressant. Most malignant tumor cells can escape host immune surveillance and promote their own development through excessive production of TGFβ. Summary of the invention
[0005] In view of this, the present invention provides an enhanced TGF-βR chimeric receptor, which is formed by combining the enhanced TGF-βR chimeric receptor with an immune cell to form an enhanced chimeric antigen receptor immune cell, which can express both a tumor-targeting chimeric antigen receptor and a TGF-βR chimeric receptor on the membrane.
[0006] The technical solution of the present invention is as follows:
[0007] An enhanced TGF-βR chimeric receptor comprises a TGF-βR2 extracellular domain and an IL-6 receptor intracellular domain, wherein the TGF-βR2 extracellular domain and the IL-6 receptor intracellular domain are connected via a transmembrane domain.
[0008] The TGF-βR chimeric receptor comprises a TGF-βR2 extracellular domain and an IL-6 receptor intracellular domain, and the TGF-βR2 extracellular domain and the IL-6 receptor intracellular domain are connected via a transmembrane domain.
[0009] Preferably, in the above TGF-βR chimeric receptor, the IL-6 receptor intracellular domain is the IL-6 receptor subunit gp130 intracellular domain.
[0010] Furthermore, the IL-6 activation signal transduction domain is composed of the gp130 intracellular region and the CD8 receptor transmembrane region, and the IL-6 activation signal transduction domain has the function of continuously transmitting IL-6 signals depending on TGF-β binding.
[0011] Furthermore, the amino acid sequence of the gp130 intracellular region is as shown in SEQ ID NO.3, or the amino acid sequence of the gp130 intracellular region is as shown in SEQ ID NO.4; wherein the amino acid sequence as shown in SEQ ID NO.4 is the sequence after amino acid mutation.
[0012] The present invention also provides a nucleic acid molecule encoding the TGF-βR chimeric receptor.
[0013] Further, the plasmid expression cassette and the recombinant cell line are constructed to contain the above-mentioned nucleic acid molecule; wherein the expression cassette includes a chimeric antigen receptor gene fragment expression cassette and a TGF-βR chimeric receptor gene fragment expression cassette, and the two are connected by any one of T2A, P2A, E2A, F2A and IRES; preferably, T2A connection is selected, preferably T2A connection; the recombinant cell line can also contain an expression cassette. In the recombinant cell line, the antigen bound by the antigen binding domain is at least one of CLDN18.2, CD19, CD20, MUC1, EGFR, EGFRv2I, HER2, ERBB3, ERBB4, VEGFR1, VEGFR2, EpCAM, ROR1, CD44 and other antigens; preferably, CLDN18.2 is selected.
[0014] The recombinant cell line is an immune cell, such as a T cell, a monocyte, a natural killer cell, a neutrophil or a tumor infiltrating lymphocyte; preferably a T cell.
[0015] The present invention also provides a biological preparation, which contains the above-mentioned nucleic acid molecule, expression cassette or recombinant cell line; this biological preparation can be widely used to prepare drugs for treating and / or preventing tumors, cancers, etc.
[0016] The enhanced TGF-βR chimeric receptor provided by the present invention, after being chimeric in immune cells, targets malignant tumors by binding to tumor antigens, and uses the TGFβ binding domain to bind TGF-β, thereby reducing TGF-β's promotion of tumor cells and its immunosuppressive effect on immune cells, such as T cells; and uses the IL-6 activation signal transduction domain to continuously transmit IL-6 signals, thereby promoting the killing and proliferation of CAR-T cells, thereby enhancing their ability to kill tumors. Experiments have shown that the co-expression of dual chimeric antigen receptors in T cells can enable T cells to achieve better killing effects in various solid tumors with high concentrations of TGF-β. In theory, it can significantly increase the efficacy of T cells on solid tumors, promote the application of CAR-T therapy in solid tumors, and has very good application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The structural schematic diagrams of three CAR plasmid expression cassettes;
[0018] Figure 2 Flow cytometry of CAR expression levels in three types of CAR-T cells;
[0019] Figure 3 Flow cytometry of TGF-βR2 expression levels of three CAR-T cells;
[0020] Figure 4 This is the detection diagram of STAT3 phosphorylation content after three types of CAR-T cells were stimulated by TGF-β;
[0021] Figure 5 The figure shows the in vitro cell killing effect of three types of CAR-T cells and blank T cells. Implementation
[0022] The preferred embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings.
[0023] The enhanced TGF-βR chimeric receptor and the corresponding immune cell provided by the present invention express a tumor-targeting chimeric antigen receptor and a TGF-βR chimeric receptor on the immune cell membrane, and the extracellular domain of the TGF-βR chimeric receptor and the intracellular domain of the IL-6 receptor, the extracellular domain of TGF-βR2 (also expressed as TGF-βR II) and the intracellular domain of the IL-6 receptor are connected through a transmembrane domain.
[0024] The amino acid sequence of the above-mentioned TGF-βR2 extracellular domain is shown in SEQ ID NO.1.
[0025] In the TGF-βR chimeric receptor, the IL-6 activation signaling domain has the function of continuously transmitting IL-6 signals depending on TGF-β binding, and the IL-6 receptor intracellular domain is the IL-6 receptor subunit gp130 intracellular domain, and the IL-6 activation signaling domain is composed of the CD8 receptor transmembrane region and the gp130 intracellular region. Accordingly, the amino acid sequence of the CD8 receptor transmembrane region is shown in SEQ ID NO.2, and the amino acid sequence of the gp130 intracellular region is shown in SEQ ID NO.3 or SEQ ID NO.4.
[0026] The above-mentioned TGF-βR chimeric receptor can constitute the coding of a nucleic acid molecule; this nucleic acid molecule can be contained in an expression cassette (e.g., a gene expression cassette), a recombinant vector (e.g., a plasmid), a recombinant protein (e.g., a fusion protein, an antibody protein, etc.), a recombinant microorganism (e.g., Escherichia coli, a bacteriophage, etc.), a recombinant cell line (e.g., an immune cell, a CHO cell, etc.) or a biological preparation; wherein the biological preparation can also include an expression cassette, a recombinant vector, a recombinant protein, a recombinant microorganism or a recombinant cell line, etc.
[0027] In one embodiment, a chimeric antigen receptor (CAR) gene fragment expression cassette and a TGF-βR chimeric receptor gene fragment expression cassette, the two expression cassettes are connected or separated by any one of the protein elements of T2A, P2A, E2A, F2A and IRES.
[0028] In an optional embodiment, in the recombinant cell line, the antigen bound by the antigen binding domain is at least one of the antigen targets such as CLDN18.2, CD19, CD20, MUC1, EGFR, EGFRv2I, HER2, ERBB3, ERBB4, VEGFR1, VEGFR2, EpCAM, ROR1, CD44, etc., and the recombinant cell line is preferably an immune cell, such as a T cell, a monocyte, a natural killer cell, a neutrophil or a tumor infiltrating lymphocyte.
[0029] The above-mentioned biological preparations include nucleic acid molecules, expression cassettes or recombinant cell lines, and such biological preparations can be widely used in the preparation of drugs for treating and / or preventing tumors, cancers, etc.
[0030] The following is further described in detail through specific examples.
[0031] Example 1 Construction of an expression plasmid for simultaneous expression of a chimeric antigen receptor and a TGF-βR chimeric receptor
[0032] like Figure 1 As shown in Figure 2, the plasmid expressing only the CAR gene fragment targeting CLND18.2 was named pLV-CAR (i.e. Figure 1The expression plasmid that simultaneously expresses the CAR gene fragment targeting CLND18.2 and the TGF-βR chimeric receptor gene fragment is named pLV-CAR-TGFR2 (i.e. Figure 1 The expression plasmid that simultaneously expresses the CAR gene fragment targeting CLND18.2 and the TGF-βR chimeric receptor mutant gene fragment is named pLV-CAR-TGFR2m (i.e. Figure 1 LV-CAR-TGFR2m in .
[0033] CAR gene fragments targeting CLND18.2 (such as Figure 1 As shown in the LV-CAR structure in Figure 2, it is composed of scFv, CD8αTM (i.e., the above-mentioned CD8), 4-1BB, and CD3ζ in sequence.
[0034] The gene fragments of the above-mentioned TGF-βR chimeric receptor are sequentially composed of TGF-βRII ECD, CD8αTM, gp130 or gp130m, wherein the amino acid sequence of each fragment is as follows:
[0035] The amino acid sequence of the extracellular segment of the TGF-βRII ECD receptor is shown in SEQ ID NO.1;
[0036] The amino acid sequence of CD8αTM (transmembrane region) is shown in SEQ ID NO. 2;
[0037] The amino acid sequence of the gp130 signal region is shown in SEQ ID NO. 3;
[0038] The amino acid sequence of the gp130m signal region mutant is shown in SEQ ID NO.4:
[0039] in:
[0040] The amino acid sequence shown in SEQ ID NO.1 is as follows:
[0041] TIPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDN2FSEEYNTSNPDLLLVIFQ;
[0042] The amino acid sequence shown in SEQ ID NO.2 is as follows:
[0043] MALPVTALLLPLALLLHAARP;
[0044] The amino acid sequence shown in SEQ ID NO.3 is as follows:
[0045] NKRDLIKKHIWPNVPDPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPEDLKSLDLFKKEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSSTVQYSTVVHSGYRHQVPSVQVFSRS ESTQPLLDSEERPEDLQLVDHVDGGDGILPRQQYFKQNCSQHESSPDISHFERSKQVSSVNEEDFVRLKQQISDHISQSCGSGQMKMFQEVSAADAFPGGTEGQVERFETVGMEAATDEGMPKSYLPQTVRQGGYMPQ;
[0046] The amino acid sequence shown in SEQ ID NO.4 is as follows:
[0047] NKRDLIKKHIWPNVPDPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPEDLKSLDLFKKEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSSTVQFSTVVHSGYRHQVPSVQVFSRS ESTQPLLDSEERPEDLQLVDHVDGGDGILPRQQYFKQNCSQHESSPDISHFERSKQVSSVNEEDFVRLKQQISDHISQSCGSGQMKMFQEVSAADAFPGGTEGQVERFETVGMEAATDEGMPKSYLPQTVRQGGYMPQ.
[0048] Example 2 Recombinant Lentivirus Packaging
[0049] The four plasmids, including the pLV-CAR plasmid, the lentiviral envelope plasmid pMD2.G (Addgene, Plasmid, #12259), the lentiviral packaging auxiliary plasmid pMDLg / pRRE (Addgene Plasmid, #12251) and pRSV-Rev (Addgene Plasmid, #12253) prepared in Example 1, were transferred into 293T cells for lentiviral packaging under the action of the transfection agent Lipofectamine 3000 to prepare the lentiviral complete expression vector LV-CAR.
[0050] The four plasmids, including the pLV-CAR-TGFR2 plasmid, the lentiviral envelope plasmid pMD2.G (Addgene, Plasmid, #12259), the lentiviral packaging auxiliary plasmid pMDLg / pRRE (Addgene Plasmid, #12251) and pRSV-Rev (Addgene Plasmid, #12253) prepared in Example 1, were transferred into 293T cells for lentiviral packaging under the action of the transfection agent Lipofectamine3000 to prepare the lentiviral complete expression vector LV-CAR-TGFR2.
[0051] The four plasmids, pLV-CAR-TGFR2m, lentiviral envelope plasmid pMD2.G (Addgene, Plasmid, #12259), lentiviral packaging auxiliary plasmid pMDLg / pRRE (Addgene Plasmid, #12251) and pRSV-Rev (Addgene Plasmid, #12253) prepared in Example 1, were transferred into 293T cells for lentiviral packaging under the action of transfection agent Lipofectamine3000 to prepare the lentiviral complete expression vector LV-CAR-TGFR2m.
[0052] The above three lentiviral supernatants were collected at 48 h and 72 h, respectively, and the collected lentiviral supernatants were concentrated by ultracentrifugation (Merck Millipore) to obtain three concentrated lentiviruses, namely, LV-CAR, LV-CAR-TGFR2 and LV-CAR-TGFR2m.
[0053] Example 3 Preparation of CAR-T cells
[0054] 1. Acquisition of T cells
[0055] Mononuclear cells were isolated from donor peripheral blood and centrifuged by density gradient centrifugation using the ficoll method. T cells were enriched using a T cell sorting kit, such as CD3 MicroBeads, human-lyophilized or 130-097-043, and activated, cultured and expanded using magnetic beads coupled to anti-CD3 / anti-CD28.
[0056] 2. T cell expansion and culture
[0057] T cells were cultured using TexMACS GMP Medium (Miltenyi Biotec, 170-076-309), which contained 10% FBS, 2 mM L-glutamine, and 100 IU / ml rhIL2. When cells were statically cultured, they were placed in a 37°C, 5% CO2 constant temperature incubator.
[0058] The concentrated recombinant lentivirus LV-CAR, LV-CAR-TGFR2 and LV-CAR-TGFR2m obtained in Example 2 were used to infect activated T cells, respectively, to obtain CAR-T cells expressing only CAR (named CAR-T-CLDN18.2), CAR-T cells expressing both CAR and TGF-βR chimeric receptors (named CAR-T-TGFR2), and CAR-T cells expressing both CAR and TGF-βR chimeric receptor mutants (named CAR-T-TGFR2m).
[0059] The CAR expression of the three CAR-T cells obtained above is as follows Figure 2 As shown, the CAR positivity rate of the control sample CAR-T-CLDN18.2 was 63.07%, the CAR-T-TGFR2 positivity rate was 60.67%, and the CAR-T-TGFR2m positivity rate was 58.97%. Figure 2 It can be seen that the CAR expression positivity rates of the three types of cells are close, which facilitates the subsequent activity detection of CAR-T cells.
[0060] The expression of TGF-βR2 on the three CAR-T cells obtained above is as follows Figure 3 As shown, the expression level of TGF-βR2 of the control sample CAR-T-CLDN18.2 was 3.48%, the expression level of TGF-βR2 of CAR-T-TGFR2 was 60.20%, and the expression level of TGF-βR2 of CAR-T-TGFR2m was 54.80%. Figure 3 It can be seen that the expression level of TGF-βR2 of CAR-T-TGFR2 and that of TGF-βR2m are similar, which is convenient for the subsequent activity detection of CAR-T cells.
[0061] Depend on Figure 2 and 3 It can be seen that the expression of TGF-βR2 does not affect the expression of CAR.
[0062] Example 4 Detection of intracellular phosphorylated STAT3 expression after CAR-T cells were stimulated by TGF-β
[0063] Blank T cells and three CAR-T cells (i.e., CAR-T-CLDN18.2, CAR-T-TGFR2, and CAR-T-TGFR2m) prepared in Example 3 were respectively cultured at 2×10 4 The cells were cultured in 24-well plates and stimulated with 5 ng / ml TGF-β for 12 h. The intracellular STAT3 phosphorylation content was detected by flow cytometry. Figure 4 As shown, the STAT3 phosphorylation content in the control sample CAR-T-CLDN18.2 was 0.52%, the STAT3 phosphorylation content in CAR-T-TGFR2 was 47.10%, and the STAT3 phosphorylation content in CAR-T-TGFR2m was 60.24%. Figure 4 It can be seen that after CAR-T-TGFR2m is stimulated by TGF-β, the phosphorylation level of STAT3 is enhanced and the cell activity can be stimulated.
[0064] Example 5 Detection of the tumor killing effect of CAR-T cells in vitro
[0065] Figure 5 The detection curve of the killing effect on gastric cancer cells is shown in Figure 2. After the positive rates of the blank T cells prepared in Example 3 and the above three CAR-T cells (i.e., CAR-T-CLDN18.2, CAR-T-TGFR2, and CAR-T-TGFR2m) were adjusted to be consistent, they were used as effector cells and were respectively measured at 1×10 4 The target cells HGC-27 (human gastric cancer cell line, stably expressing Claudin18.2 using lentivirus) were added to the low adsorption well plate at a ratio of 10:1, 3:1, 1:1, and 0.3:1. The corresponding number of CAR-T cells was added at the same time as 5 ng / ml TGF-β. The specific killing rate was calculated according to the following formula:
[0066] Specific killing rate (%) = (LDH value of experimental well - LDH value of natural release well) / (LDH value of maximum release well - LDH value of natural release well).
[0067] The specific killing rate results of the three CAR-T cells are as follows Figure 5 As shown, the killing rate of CAR-T-TGFR2m on gastric cancer cells was significantly higher than that of CAR-T-TGFR2 and CAR-T-CLDN18.2, indicating that the specific modification of the TGFR2m gene fragment in the CAR-T cells of the present invention was successful.
[0068] It should be understood that the above description of the preferred embodiments of the present invention is relatively detailed and cannot be regarded as limiting the scope of patent protection of the present invention. The scope of patent protection of the present invention shall be based on the attached claims.
Claims
1. An enhanced TGF-βR chimeric receptor, It is characterized in that The gene fragment of the TGF-βR chimeric receptor is composed of the TGF-βRII ECD receptor extracellular segment, the CD8αTM transmembrane region, the gp130 signal region or the gp130m signal region in sequence; wherein the amino acid sequence of the TGF-βRII ECD receptor extracellular segment is shown in SEQ ID NO.1, the amino acid sequence of the CD8αTM transmembrane region is shown in SEQ ID NO.2, the amino acid sequence of the gp130 signal region is shown in SEQ ID NO.3, and the amino acid sequence of the gp130m signal region mutant is shown in SEQ ID NO.
4.
2. A nucleic acid molecule, It is characterized in that The nucleic acid molecule encodes the TGF-βR chimeric receptor according to claim 1.
3. An expression cassette, It is characterized in that The expression cassette comprises the nucleic acid molecule of claim 2.
4. A recombinant cell line, It is characterized in that The recombinant cell line comprises the nucleic acid molecule of claim 2, or comprises the expression cassette of claim 3.
5. A biological agent, It is characterized in that The biological preparation comprises the nucleic acid molecule of claim 2, or comprises the expression cassette of claim 3, or comprises the recombinant cell line of claim 4.
6. Use of the biological preparation according to claim 5 in the preparation of drugs for gastric cancer.
